Vaniam Group Welcomes Meredith Keyes, CPA, as Chief Financial Officer to Propel Strategic Growth and Innovation

Accomplished Life Sciences Financial Leader Joins to Scale Infrastructure and Drive Strategic Value

CHICAGO, Oct. 7, 2025 /PRNewswire/ -- Vaniam Group, a leading and growing healthcare communications organization specializing in oncology and rare diseases, is pleased to announce the appointment of Meredith Keyes, CPA, as Chief Financial Officer. This leadership addition reinforces the company's commitment to scaling its operational and financial infrastructure to support its continued growth, innovation, and client impact.

"Vaniam Group has thrived as a trusted partner to biotech and pharmaceutical companies advancing transformative therapies, thanks to our dedication to scientific integrity and outcome-centered innovation," said Deanna B. van Gestel, CEO of Vaniam Group. "Adding a financial leader of Meredith's caliber aligns with our mission to scale responsibly while delivering unparalleled client value. Her expertise in the life sciences sector and her success in driving growth will enhance our ability to support the progress of our clients and their transformative therapies."

Meredith Keyes brings more than 20 years of distinguished financial leadership, including multiple CFO roles within high-growth, life sciences-focused organizations, such as BioBridges and OPEN Health. She has an impressive record of optimizing financial operations, executing strategic M&A, and fostering innovation—all relevant experience as Vaniam Group strengthens its position as a leader in its field. A recipient of the Triangle Business Journal CFO Award, Keyes earned her Master of Accounting from the University of North Carolina's Kenan-Flagler Business School.

With this appointment, Vaniam Group signals its readiness to advance to the next stage of its growth journey. Already recognized as a thoughtfully scaling, innovation-driven company, Vaniam Group is poised to continue supporting its biotech and pharmaceutical partners with the strategic financial leadership Keyes will provide.

"Vaniam Group occupies a unique place in the medical communications landscape—harmonizing scientific rigor with creativity and purpose," Keyes said. "I am energized to enhance the financial frameworks that underpin this incredible organization, leaving it even better positioned to tackle the increasingly complex needs of our biotech and pharmaceutical partners and to elevate oncology and rare disease care."

Aligned with Vaniam Group's vision for sustained impact and innovation, Keyes's leadership will empower the organization to further anticipate the evolving needs of its partners while laying the groundwork for transformative opportunities through thoughtful growth initiatives.

This milestone marks another significant step in solidifying Vaniam Group's standing as the trusted partner for advancing breakthrough science into actionable connections that benefit patients worldwide.

About Vaniam Group
Vaniam Group is a premier medical communications partner for biopharma innovators, dedicated to transforming complex science into meaningful connections that drive human impact. Combining deep scientific expertise, actionable insights, and cutting-edge digital solutions, Vaniam Group bridges the gap between novel therapies and the healthcare providers and patients they serve. Specializing in oncology, hematology, rare diseases, and immunology, Vaniam Group fosters collaboration, sparks dialogue, and accelerates breakthroughs in drug development and commercialization. By putting science and patients at the center, the company is shaping a future where transformative therapies find their way to the people who need them most.

To learn more about how Vaniam Group is advancing the future of healthcare, visit vaniamgroup.com.

SOURCE Vaniam Group LLC